Preparation method and application of lotus seed pot extract
By optimizing the preparation method of Lotus extract, proanthocyanin inhibits the activities of α-glycosidase and α-amylase, restoring the insulin signaling pathway, solving the side effects of traditional diabetes drugs, and achieving the effect of effectively reducing blood sugar and improving insulin resistance. It significantly affects blood lipids and liver health.
Patent Information
- Application Number
- CN202411252285.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-12-06
AI Technical Summary
Existing diabetes treatment drugs such as metformin, sulfonylureas and acarbose have hypoglycemia and gastrointestinal side effects, and their hypoglycemia mechanism has not been fully elucidated, resulting in limited clinical application and a new hypoglycemia-lowering drug is needed to Alternative or auxiliary traditional medicine.
By preparing lotus extract, using proanthocyanin as the main component, the Lotus extract was obtained by optimizing the extraction of ethanol at different concentrations, the extraction time and temperature, and used to inhibit the activities of α-glycosidase and α-amylase. Restores liver insulin signaling pathways, lowers blood sugar, improves insulin resistance, and significantly affects blood lipids and liver health.
Lotus extract can effectively reduce blood sugar in db/db mice, improve insulin resistance, increase HDL, reduce LDL, reduce liver lipid accumulation and oxidative stress, improve liver antioxidant capacity, and verify its sugar-lowering capacity in vitro and in vivo and the effect of lipid reduction.
Smart Images

Figure CN119074805A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of drug preparation, and more specifically to a preparation method and application of a lotus seed pod extract. Background Art
[0002] Metformin can inhibit hepatic gluconeogenesis, promote the uptake and utilization of glucose by the liver and muscle tissue, and thus improve the body's insulin sensitivity. Sulfonylurea drugs can stimulate pancreatic β cells to increase insulin secretion, thereby lowering blood sugar. Acarbose can inhibit the activity of α-glucosidase in the small intestine and delay intestinal absorption of glucose. However, side effects such as hypoglycemia and gastrointestinal reactions limit the clinical application of these drugs. In recent years, many scholars have begun to pay attention to the pharmacological effects of natural active ingredients in plants because they have multi-target and multi-pathway characteristics, definite efficacy, and no side effects. A large number of studies have found that proanthocyanidins are effective in the treatment of diabetes, improving diabetic conditions and lowering blood sugar through different pathways and mechanisms, with relatively few side effects, and have the prospect of being developed as intervention drugs for diabetes.
[0003] The whole lotus plant is a treasure, but the value of lotus pods has not been valued by the food industry. Laboratory preliminary studies have shown that lotus pod extracts have a significant hypoglycemic effect, but the specific molecular mechanism has not yet been elucidated. Therefore, in-depth exploration of the pharmacological properties of the active ingredients in lotus pods and their hypoglycemic molecular mechanism is of great significance for the development of new hypoglycemic health foods. Summary of the invention
[0004] The purpose of the present invention is to provide a preparation method and application of lotus seed pod extract to solve the above technical problems.
[0005] The above technical purpose of the present invention is achieved through the following technical scheme: a preparation method of lotus pod extract, taking lotus pod, washing, drying in a drying oven at 55°C for 8h, and then pulverizing with a crusher, storing the powder after passing through a 100-mesh sieve in a frosted wide-mouth bottle, sealing it, and placing it in a refrigerator at 4°C for standby use; taking 1g of lotus pod powder, adding 60% ethanol solution according to a solid-liquid ratio of 1:12, shaking well, static extraction for 2.5h, the extraction temperature is 40°C, centrifuging at 10000r·min, 4°C for 10min, taking out the supernatant, and obtaining lotus pod extract proanthocyanidins.
[0006] The present invention further provides an application of the lotus pod extract: PB2, a main component in the lotus pod extract, reduces blood sugar in db / db mice and improves insulin resistance by restoring the liver insulin signaling pathway.
[0007] The present invention is further configured as follows: the lotus pod extract can be used to inhibit the activities of α-glucosidase and α-amylase.
[0008] The present invention is further configured as follows: a high dose of the lotus seed pod extract can increase the HDL content in blood lipids and significantly reduce the LDL content.
[0009] The present invention is further configured as follows: the lotus pod extract can reduce liver lipid accumulation, liver damage and oxidative stress in db / db mice, reduce the expression levels of ALT and AST, increase the expression levels of liver SOD, CAT and GSH, and reduce the level of MDA.
[0010] The present invention is further configured as follows: PB2, a main component in the lotus pod extract, can be used to promote HepG2 liver cells to consume glucose.
[0011] The present invention is further configured as follows: the lotus pod extract improves insulin resistance, upregulates IRS-1 and AKT phosphorylation, restores insulin signaling pathway conduction, and then activates downstream signaling pathways, increases GLUT2 expression and promotes glucose uptake; induces GSK-3β phosphorylation to promote glycogen synthesis; and downregulates PEPCK and G6pase to reduce glucose production.
[0012] The present invention further provides application of the lotus seed pod extract in preparing hypoglycemic drugs, health products and hypoglycemic foods.
[0013] In summary, the present invention has the following beneficial effects:
[0014] (1) The proanthocyanidins in lotus pods were extracted using ethanol of different concentrations. The optimal extraction method for lotus pod extract was found through single factor and orthogonal experiments. The yield of proanthocyanidins was the highest when the ethanol volume fraction was 60%, the solid-liquid ratio was 1:12, the extraction time was 2.5 h, and the extraction temperature was 40°C.
[0015] Then, the inhibitory effect of lotus seed pod extract LSE on α-glucosidase and α-amylase was detected to explore its hypoglycemic ability in vitro. The IC50 value of LSE on α-amylase was 0.35 mg / mL, which was stronger than acarbose (0.62 mg / mL), but the IC50 value on α-glucosidase was 15 μg / mL, which was weaker than acarbose.
[0016] (2) The db / db T2DM model mice were fed with the lotus pod ethanol extract, and their blood glucose, insulin resistance index and other indicators were detected. Finally, the protein immunoblotting technique was used to analyze the expression of insulin resistance signaling pathway-related proteins in the mouse liver to verify its hypoglycemic molecular mechanism in animals.
[0017] (3) An insulin resistance model was established using glucosamine and HepG2 liver cells. The main active ingredients in the lotus seed pod extract were analyzed using high performance liquid chromatography, and then the insulin resistance cell model was treated with the main active ingredients. Finally, protein immunoblotting was used to analyze the expression of insulin resistance signaling pathway proteins to determine its cellular and molecular mechanism of hypoglycemia.
[0018] (4) The mechanism of action of lotus pod extract in lowering blood sugar was revealed, which provided a theoretical basis for the subsequent use of lotus pod extract in the research and development of drugs, health products and foods for the treatment of hypoglycemia. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 The effect of ethanol concentration on the yield of proanthocyanidins in Example 1 of the present invention;
[0020] Figure 2 The effect of the material-liquid ratio on the yield of proanthocyanidins in Example 1 of the present invention;
[0021] Figure 3 The effect of extraction time on the yield of proanthocyanidins in Example 1 of the present invention;
[0022] Figure 4 The effect of extraction temperature on the yield of proanthocyanidins in Example 1 of the present invention;
[0023] Figure 5 The inhibition of α-amylase by LSE and acarbose in Example 2 of the present invention;
[0024] Figure 6 The inhibition of α-glucosidase by LSE and acarbose in Example 2 of the present invention;
[0025] Figure 7 is the effect of LSE on blood glucose in db / db mice in Example 2 of the present invention;
[0026] Figure 8 is the effect of LSE on the insulin resistance index of db / db mice in Example 2 of the present invention;
[0027] Fig. 9 It is the hematoxylin and eosin staining (200 times) of the liver tissues of different groups of mice in Example 2 of the present invention; (A) Nor (B) MOD (C) MET (D) L-LSE (E) H-LSE;
[0028] Fig.10The effect of LSE on the expression of insulin signaling pathway proteins in the liver of db / db mice in Example 2 of the present invention; (A) protein band diagram of mouse liver tissue; (B) p-IRS1 / IRS1; (C) p-AKT / AKT; (D) p-GSK3β / GSK3β; (E) PEPCK; (F) G6pase; (G) GLUT2;
[0029] Fig.11 The toxicity of different concentrations of GlcN on HepG2 cells in Example 2 of the present invention, Note: *, P<0.05; **, P<0.01, the same below;
[0030] Fig.12 The effect of different concentrations of GlcN on glucose absorption of HepG2 cells in Example 2 of the present invention;
[0031] Fig.13 The effect of different induction times of GlcN on glucose absorption of HepG2 cells in Example 2 of the present invention;
[0032] Fig.14 (A) is the retention time of the standard PB1 / PB1 / PB4 in Example 2 of the present invention; Fig.14 Middle (B) is the analysis of the contents of three kinds of oligomeric proanthocyanidins in the alcohol extract of lotus pods in Example 2 of the present invention;
[0033] Fig.15 The cytotoxic effects of LSE and PB2 on HepG2 cells in Example 2 of the present invention;
[0034] Fig.16 is the effect of PB2 and LSE on HepG2-IR in Example 2 of the present invention;
[0035] Fig.17 The effect of PB2 in Example 2 of the present invention on the expression of insulin signaling pathway proteins in glucosamine-induced HepG2 insulin-resistant cells; (A) HepG2 hepatocyte protein band diagram; (B) p-IRS1 / IRS1; (C) p-AKT / AKT; (D) p-GSK3β / GSK3β; (E) PEPCK; (F) G6pase; (G) GLUT2. DETAILED DESCRIPTION
[0036] The following is combined with Figure 1-17 The present invention is described in further detail.
[0037] Example 1: A method for preparing lotus seed pod extract
[0038] Taking the total yield of proanthocyanidins as an indicator, four factors, namely, ethanol concentration, solid-liquid ratio, extraction time and extraction temperature, were investigated. According to the results of the preliminary experiment, when the other parameters were fixed, the following ethanol concentrations were investigated: 0%, 20%, 40%, 60%, 80%; solid-liquid ratio (mass to volume): 1:5, 1:8, 1:10, 1:12, 1:15 and 1:20; extraction time: 0.5, 1, 1.5, 2 and 2.5h; extraction temperature: 20, 40, 60, 80 and 100℃.
[0039] The effect of ethanol volume fraction on the yield of proanthocyanidins is Figure 1 It can be seen that within the range of ethanol volume fraction of 0% to 60%, the yield of proanthocyanidins increases with the increase of ethanol volume fraction, and when the ethanol volume fraction is 60%, the yield is 480.25mg / g, reaching the maximum value, but when the ethanol volume fraction is greater than 60%, the extraction yield decreases with the increase of ethanol volume fraction. This is because with the change of ethanol-water volume fraction, the polarity of the solvent also changes, the dissolution rate of proanthocyanidins changes, and different ethanol aqueous solutions have different effects on the structure of tissue cells. At the same time, the reduction of water also weakens the swelling of granular cells. Therefore, when the ethanol volume fraction is increased to a certain extent, the extraction rate of proanthocyanidins decreases. When the volume fraction is 80%, the yield of proanthocyanidins is 443.86mg / g, which is 7.5% lower than the yield of proanthocyanidins when the ethanol volume fraction is 60%.
[0040] Depend on Figure 2 It can be seen that when the solid-liquid ratio is in the range of 1:5-1:12, the yield of proanthocyanidins is constantly increasing. When the solid-liquid ratio is 1:12, the yield of proanthocyanidins is the highest, which is 444.23 mg / g; but when the solid-liquid ratio is in the range of 1:12-1:20, the yield of proanthocyanidins decreases. When the solid-liquid ratio is 1:20, the yield of proanthocyanidins is 388.51 mg / g.
[0041] The effect of extraction time on the yield of proanthocyanidins is Figure 3 It can be seen that when the soaking time is in the range of 0.5-2h, the yield of proanthocyanidins gradually increases. At 2h, the yield of proanthocyanidins reaches the maximum, which is 490.07mg / g. This is because the longer the extraction time, the more proanthocyanidins will dissolve into the extract. When the time is 2.5h, the yield of proanthocyanidins decreases instead, which may be because the proanthocyanidins are stored in the solvent for too long and are oxidized and destroyed.
[0042] The effect of extraction temperature on the yield of proanthocyanidins is Figure 4It can be seen that in the temperature range of 20-60°C, as the temperature continues to increase, the yield also continues to increase. When the temperature is 60°C, the yield is the largest, which is 430.17 mg / g. This may be because the higher the water bath temperature, the stronger the solubility of proanthocyanidins in the solvent, and more proanthocyanidins are dissolved in the extract; but when the water bath temperature is 100°C, the yield of proanthocyanidins is reduced to 352.54 mg / g. This may be because the proanthocyanidins are kept at a high temperature for too long and are destroyed by oxidation.
[0043] On the basis of the above single factor experiment, the L9 (34) orthogonal experiment was used to optimize the conditions of the four factors of ethanol volume fraction, solid-liquid ratio, extraction time and extraction temperature, as shown in Tables 1 and 2. After obtaining the optimal process conditions, the process parameters were modified in combination with actual applications and three verification tests were carried out.
[0044] Table 1. Response surface experimental design factor level table
[0045]
[0046] Table 2 Orthogonal test design and test results
[0047]
[0048] According to the range analysis, when the combination is A2B2C3D1, that is, the ethanol volume fraction is 60%, the solid-liquid ratio is 1:12, the extraction time is 2.5h, and the extraction temperature is 40℃, the yield of proanthocyanidins is the highest. However, this combination does not appear in the above-mentioned orthogonal experimental combination, so it is verified under this process condition, and the yield of proanthocyanidins under the optimal combination extraction conditions is (528.4±12.9) mg / g. Compared with the extraction conditions of the prior art, that is, 40% ethanol solution, solid-liquid ratio is 1:8, extraction time is 1.5h, extraction temperature is 40℃, and the proanthocyanidin yield obtained under the conditions of one extraction is 418.65mg / g, and the yield after optimization is 1.26 times that before optimization.
[0049] Example 2: Application of a lotus seed pod extract
[0050] 1. Inhibition of digestive enzymes in vitro
[0051] (1) Amylase inhibition method
[0052] The DNS (3,5-dinitrosalicylic acid) colorimetric method is used. The principle is that α-amylase can hydrolyze starch into reducing sugar, and the reducing sugar then reacts with 3,5-dinitrosalicylic acid. The final product is reddish brown. The colorimetry is performed at 540 nm, and the activity of α-amylase is determined based on the relative change in absorbance.
[0053] 2U / mL α-amylase solution was prepared with PBS solution of pH 6.8, and then PBS and DMSO were mixed in a ratio of 9:1 as buffer, and lotus seed pod extracts with concentrations of 0.05, 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, and 1.2 mg / mL were prepared. 100 μL of each mass concentration was taken, and 50 μL of α-amylase was added, and the reaction was incubated in a 37°C water bath for 20 minutes. Then 3% starch solution was added as substrate, and enzymolysis was performed in a 37°C water bath for 15 minutes. 500 μL DNS was added to terminate the reaction, and the mixture was boiled in a boiling water bath for 5 minutes, cooled rapidly, and 200 μL was taken to make the volume 1mL, and the absorbance was measured at 540nm, recorded as (A1), and the absorbance value (A0) was measured using buffer as a blank control. The enzyme inhibition test was repeated 3 times, and the above operation was repeated with acarbose as a positive control.
[0054] Amylase inhibition rate (%) = (A0-A1) / A0×100%
[0055] By fitting the curve of enzyme activity inhibition rate and sample concentration, the half inhibition rate concentration IC50 of lotus seed pod extract and the IC50 of acarbose were analyzed and obtained.
[0056] like Figure 5 As shown in the results, LSE (Lotus seed extract) has a significant dose-dependent inhibitory effect on the activity of α-amylase. When the concentration is 1.2 mg / mL, the maximum inhibition rate is 66.98%, which is higher than the maximum inhibition rate of the positive control acarbose (60.07%). Further calculation shows that the half inhibition concentration IC50 value is 0.35 mg / mL, which is stronger than acarbose (0.62±0.01 mg / mL).
[0057] (2) Glucosidase inhibition method
[0058] The experimental principle is that PNPG (p-nitrophenyl-α-D-pyranoglucoside) is composed of one molecule of glucose and one molecule of p-nitrophenol through a glycosidic bond. α-glucosidase hydrolyzes PNPG to produce p-nitrophenol (PNP), which is yellow and has a characteristic absorption peak at 405nm.
[0059] The specific method is to prepare 1.0U / mL α-glucosidase solution with PBS solution of pH 6.8, mix PBS and DMSO in a ratio of 9:1 as a buffer, prepare lotus seed pod extracts with concentrations of 5, 10, 20, 40, 80, 100, 120, 150, and 200μg / mL, take 50μL of each mass concentration, add 100μL α-glucosidase, incubate the reaction in a 37℃ water bath for 10min, then add 50μL of 3.0mM PNPG solution as a substrate for 20min, finally add 1mL 0.1mol / L sodium carbonate solution to terminate the reaction, and measure its absorbance at 405nm (A1) with an enzyme reader, and measure its absorbance value (A0) with a buffer as a blank control. The enzyme inhibition test was repeated 3 times, and acarbose was used to repeat the above operation as a positive control.
[0060] α-Glucosidase inhibition rate (%) = (A0-A1) / A0×100%
[0061] The enzyme activity inhibition rate-sample concentration curve was fitted and then analyzed to obtain the half inhibition rate concentration IC50 of lotus seed pod extract and the IC50 of acarbose.
[0062] LSE has a stronger inhibitory effect on the activity of α-glucosidase, which exceeds the inhibitory effect on α-amylase. Figure 6 The results showed that when the concentration of LSE was 80 μg / mL, the inhibition rate of α-glucosidase reached 87.57%, and the maximum inhibition rate was 89.62%, but it was lower than the maximum inhibition rate of acarbose in the positive control group (97%). The activity of acarbose on α-glucosidase was 96% at 5 μg / mL, which had a very strong inhibitory effect. The half inhibition concentration IC50 value was further calculated, and the IC50 value of LSE was 15 μg / mL.
[0063] 2. Animal hypoglycemic test
[0064] (1) Establishment of type II diabetes mouse model
[0065] Thirty-two SPF 8-week-old male db / db mice. Eight normal 8-week-old male C57BL / 6 mice. db / db mice are type II diabetic mice caused by leptin receptor gene defects. No human interference is required. The feeding conditions are the same as those of normal C57BL / 6 mice. Type II diabetes can be spontaneously produced after 8 weeks. After fasting for 12 hours, fasting blood glucose higher than 11.1mmol / L represents successful modeling, and the mice are randomly divided into 4 groups. Model control group (MOD), metformin group (MET), LSE low-dose group (L-LSE), LSE high-dose group (H-LSE). Take an additional 8 C57BL / 6 mice of the same age as the normal control group (Normol). Each group of mice was gavaged with drugs once a day at 20mL / kg.
[0066] Table 3 Dosage settings
[0067]
[0068] (2) Physiological and biochemical index detection
[0069] During the experiment, the blood glucose of mice was monitored regularly every week. After administration, the mice were fasted for 12 hours and blood was collected from the tail for measurement.
[0070] After 11 weeks of administration, fast for 12 hours, then collect blood from the eye sockets, centrifuge at 3000rpm for 10 minutes to obtain serum, and store it in a -80℃ refrigerator for testing. Mouse serum was tested according to the instructions of triglyceride (TG) test kit, total cholesterol (CHO) test kit, low-density lipoprotein cholesterol (LDL) test kit, high-density lipoprotein cholesterol (HDL) test kit, aspartate aminotransferase (AST / GOT) test kit, and alanine aminotransferase (ALT / GPT) test kit. Mouse liver was tested according to the instructions of malondialdehyde (MDA), total superoxide dismutase (SOD), catalase (CAT), reduced glutathione (GSH), etc.
[0071] Experiments have shown that LSE can reduce fasting blood glucose in db / db diabetic mice. Figure 7 As shown in the figure, the fasting blood glucose of the blank control group was 7.2±1.0mmol / L, and that of the model group was 25.6±5.3mmol / L, with significant differences between the two groups (P<0.05). Daily intragastric administration of 300mg / kg of metformin can significantly reduce the blood glucose of diabetic mice, from 25.6±5.3mmol / L to 15.0±2.6mmol / L. LSE also had a similar effect, reducing blood glucose in a dose-dependent manner, with a low dose of 17.3±5.3mmol / L and a high dose of 16.0±4.1mmol / L, which was significantly different from the model group (P<0.05).
[0072] like Figure 8 As shown, the db / db mice in the model group had severe insulin resistance, with an insulin resistance index of 71.7±13.6, while the blank control group had only 4.4±1.8. Metformin was more effective than LSE in reducing the insulin resistance index, which was 15.2±5.0, with a very significant difference (P<0.01), while the low-dose and high-dose groups were 26.6±2.9 and 24.2±10.7, respectively, which were very significantly different from the model group (P<0.01).
[0073] As shown in Table 4, compared with the normal group of mice, the total cholesterol (CHO) and low-density lipoprotein cholesterol (LDL) of the db / db model group mice increased significantly (P<0.01). However, triglycerides (TG) had almost no effect. After treatment with MET and LSE, compared with the MOD group, the high-density lipoprotein cholesterol (HDL) content increased and the LDL content decreased, among which the H-LSE group had a very significant difference (P<0.05). Although CHO, LDL, and HDL have no direct connection with the cause of type II diabetes, type II diabetes can increase the risk of cardiovascular disease by 2-4 times, while lowering LDL is beneficial to reducing the risk of cardiovascular disease.
[0074] Table 4 Effects of LSE on four blood lipids in db / db mice
[0075]
[0076] In Table 5, the serum and liver oxidative stress related indicators of db / db diabetic mice were analyzed. Long-term hyperglycemia leads to liver metabolic disorders and liver damage, which can be indicated by ALT (alanine aminotransferase) and AST (aspartate aminotransferase). The ALT and AST in the model group were much higher than those in other groups, 132.89±5.78 (U / L) and 135.34±5.34U / L, respectively, both exceeding 40U / L, indicating that type II diabetes caused severe liver damage to db / db mice, which was significantly different from other groups (P<0.01). The ALT and AST of the blank control mice were 14.46±0.85U / L and 23.81±3.52U / L, respectively. The metformin group and the high and low doses of lotus seed can reduce the ALT and AST content in serum. High doses of LSE can restore ALT and AST to normal levels, 25.73±2.80U / L and 24.18±0.23U / L, respectively.
[0077] Table 5 Effects of LSE on the liver of db / db mice
[0078]
[0079] (3) Histomorphological analysis
[0080] After the mouse feeding experiment, the liver tissues of each group of mice were taken, fixed with 4% paraformaldehyde for 24 hours, and then embedded in paraffin. The liver samples were then processed with a low-temperature thermostat for preparation, and after hematoxylin-eosin (H&E) staining, the sections were finally observed and photographed with a pathological imaging system.
[0081] Fig. 9 The photo of H&E staining of mouse liver tissue is shown (magnified 200 times). As can be seen from the figure, hematoxylin stains the cell nucleus blue-purple and eosin stains the cytoplasm pink. Compared with the Nor group, the liver of the MOD group showed hepatocyte expansion caused by fat accumulation, severe cell degeneration and loss of cell boundaries. After MET treatment, liver damage and vacuoles were significantly reduced. The L-LSE and H-LSE groups showed liver tissue structure similar to that of the MET group, well-preserved cytoplasm, clear nucleoli, and significant improvement in liver damage. These results prove that after db / db mice ingest LSE, they can reduce liver fat deposition and liver damage associated with type 2 diabetes.
[0082] (4) Western blotting
[0083] Weigh about 20 mg of mouse liver tissue, and then add RIPA lysis buffer at a ratio of 1:10 (add 100×PMSF, 100×protease inhibitor, and 100×phosphorylase inhibitor before use). Grind on ice for 1 minute, then continue to lyse for 15 minutes, and finally centrifuge at 12000xg for 15 minutes. Pipette the supernatant into a new centrifuge tube, record the volume, and set aside. Determine the protein concentration of each sample by the BCA method, and then use PBS to adjust the above protein concentrations to be consistent to ensure that the total mass of the protein loaded on the subsequent electrophoresis is the same. Add 4× protein loading buffer according to the sample volume and cook the sample at 100℃ for 10 minutes. Take out, quickly put it in ice cubes to cool, and then store it at -20℃ for use.
[0084] 1) The protein lysis steps are as follows:
[0085] Add WB lysis buffer (add 100×PMSF, 100×protease inhibitor, 100×phosphatase inhibitor before use). For cells cultured in 6-well plates, add 150-200μL / well. Lyse on ice for 5 minutes, scrape with a cell scraper, transfer to a 2mL centrifuge tube, and continue lysing for 15 minutes. Turn on the refrigerated centrifuge in advance for precooling. Centrifuge at 12000xg for 15 minutes. Pipette the supernatant into a new centrifuge tube, record the volume, and set aside. Determine the protein concentration of each sample by the BCA method, and then use PBS to adjust the above protein concentrations to be consistent to ensure that the total mass of the protein loaded on the subsequent electrophoresis is the same. Add 4× protein loading buffer according to the sample volume, and cook the sample at 100℃ for 10 minutes. Take out, quickly put it in ice cubes to cool, and then store it at -20℃ for use.
[0086] 2) Glue making steps
[0087] Clamp the glass plates and prepare the separation gel according to the following formula. Add 4.5mL of separation gel to each glass plate, and then add 1-2mL of isopropanol to seal the gel. After the separation gel solidifies, discard the isopropanol. Prepare the concentrated gel according to the formula, mix well and quickly add it, insert the 15-hole sample comb. Let it stand for 1 hour before use, or put it in a 4℃ refrigerator and use it within one week.
[0088] Table 6 Glue making formula
[0089]
[0090] 3) Electrophoresis
[0091] Assemble the electrophoresis tank and add 1× electrophoresis buffer. Take the prepared sample out of the refrigerator, dissolve it, mix it and centrifuge it. Remove the sample comb and add 8μL of sample to each well. After assembling the electrophoresis device, set the electrophoresis conditions to: normal pressure electrophoresis, 70V, 110min.
[0092] 4) Transfer
[0093] Prepare the PVDF membrane and transfer buffer in advance, cut it with a knife, mark the upper left corner with a pencil, pour in methanol to activate for more than 30 seconds, then pour out the methanol, and add ultrapure water to rinse twice. Pour the cooled 1× transfer buffer into a white porcelain dish. Assemble in the order of black clips, sponges, filter paper, adhesive strips, PVDF membrane, filter paper, sponges, and white clips, and then put them in an ice box. Finally, use the constant current mode to transfer the membrane. The transfer time and current intensity depend on the molecular weight of the protein.
[0094] 5) Blocking and incubation of primary and secondary antibodies
[0095] Prepare 5% (m / v%) skim milk in advance, and place the PVDF membrane with transferred proteins in the antibody incubation box with the protein side facing up. Pour about 5mL skim milk and block on a shaker at a speed of 50 for 1h. Wash the blocked PVDF membrane once with TBST. Take another primary antibody incubation box and add 4mL of prepared primary antibody to each strip. Incubate in a 4℃ refrigerator overnight. Take it out of the refrigerator the next day and recover the primary antibody. Wash it three times with TBST (shaking speed 70), 10min each time. Prepare the secondary antibody immediately and use it immediately. Prepare the secondary antibody with skim milk at a ratio of 1:5000. Incubate the secondary antibody slowly on a shaker at room temperature for 1h, and then wash it three times with TBST, 10min each time.
[0096] 6) Development and analysis
[0097] According to the required number of PVDF membranes, ECL developer was prepared, and the membranes were exposed, developed and photographed using an Amersham imagequant 800 imager.
[0098] After the antioxidant signaling pathway was activated, the oxidative stress state in the liver of diabetic mice was alleviated. Fig.10 As shown in (B), the IRS-1 phosphoprotein level in the LSE group was significantly increased, with the protein expression level in the low-dose group being 1.29, while that in the model group was only 0.37, with a very significant difference (P<0.001). On the other hand, the phosphorylation expression of AKT downstream of LSE was also enhanced, with the low-dose group being 0.70, the high-dose group being 1.35, and the metformin group being 1.09. The expression level in the model group was only 0.60, which was very significantly different from the metformin group and the high-dose lotus seed pod group (P<0.01), and significantly different from the blank control group (P<0.05).
[0099] GSK-3β is a protein that controls liver glycogen synthesis. When it is phosphorylated and activated, glycogen synthase is activated, promoting liver glycogen synthesis. Fig.10 As shown in (C), the expression of GSK-3β phosphorylated protein was severely inhibited in the model group, with an expression level of 0.71, which was significantly different from the blank group (P<0.01). The metformin group and the low-dose lotus pod group both promoted the expression of GSK-3β phosphorylated protein, with expression levels of 0.96 and 0.90, respectively, while the high-dose lotus pod group was 1.04, which was significantly different from the model group (P<0.05).
[0100] The liver is an important organ that produces endogenous glucose when the body is hungry. It produces a large amount of glucose through gluconeogenesis. PEPCK and G6pase are key enzymes that regulate gluconeogenesis. When their expression levels increase, they can promote the synthesis of glucose in liver cells. Fig.10 As shown in (E), the expression level of PEPCK in the model group increased significantly to 1.36, which was significantly different from the blank control group (P<0.05). The expression levels of the metformin group and the low- and high-dose lotus seed pod groups were 1.03, 1.14, and 1.12, respectively, and returned to normal levels. Fig.10 In (F), G6pase was significantly increased in the model group, with a relative expression level of 1.19, while those in the metformin and low-dose lotus seed pod groups were 0.94 and 0.82, respectively, and those in the high-dose lotus seed pod group were 0.63. The expression level of G6pase protein was decreased, which was significantly different from that in the model group (P<0.05), which was helpful to reduce gluconeogenesis.
[0101] GLUT2 is an important channel protein for glucose to enter liver cells. Fig.10As shown in (G), the expression of GLUT2 in the liver of mice in the model group was significantly inhibited, with a relative expression of 0.45, while that in the metformin group was 0.90. The expression of the low-dose and high-dose lotus seed pod groups was increased, with a relative expression of 0.71 and 0.79, respectively, with extremely significant differences (P<0.01).
[0102] 3. Cellular hypoglycemic test
[0103] Human HepG2 cells: purchased from Procell, Wuhan, Hubei.
[0104] (1) Determination of type B proanthocyanidins: HPLC was used to simultaneously and quantitatively determine the three types of proanthocyanidins, PB1, PB2, and PB4.
[0105] 1) Chromatographic conditions
[0106] Agilent 1260HPLC system was used for detection and analysis, and WAT 054275Symmetry C18 chromatographic column (5μm 4.6×250mm Column) was used for chromatographic separation; the column oven temperature was 25°C; the automatic injection volume was 10μL, and the detection wavelength was 278nm; the mobile phases A and B were methanol and 0.3% formic acid; the mobile phase flow rate was 0.5mL / min; and the gradient elution was performed as shown in Table 7.
[0107] Table 7 Gradient elution HPLC
[0108]
[0109] 2) Preparation of test solution
[0110] Preparation of reference solution: Accurately weigh appropriate amounts of PB1, PB2, and PB4 reference substances, and add chromatographic grade methanol to prepare standard stock solutions with mass concentrations of 2.0, 1.0, and 0.5 mg / mL, respectively. The reference solutions diluted to a series of mass concentrations were filtered through a 0.45 μm microporous membrane and tested.
[0111] Preparation of test solution: The alcohol extract of lotus pod (obtained from 50% ethanol extraction) was dissolved in methanol, and then filtered through a 0.45 μm microporous filter membrane into a sample injection bottle for testing.
[0112] The polyphenols in lotus pods are mainly proanthocyanidins, which are a mixture of (+)-catechin, (-)-epicatechin, (+)-gallocatechin and (-)-epigallocatechin through different condensation methods. Among them, B-type proanthocyanidins are the main dimers. In this study, HPLC was used to analyze the content of B-type proanthocyanidin dimers PB1 / PB2 / PB4 in LSE. The characteristic peaks of the three B-type proanthocyanidins are as follows: Fig.14As shown in (A), the retention times are PB1 (20.6min), PB4 (23min), and PB2 (25.6min), respectively. Fig.14 As shown in (B), PB2 is the most abundant component in LSE, followed by PB1, and PB4 is the least abundant. The corresponding contents in LSE were calculated based on the standard curve, and the contents of PB1, PB4, and PB2 were 24.27 μg / mg, 12.57 μg / mg, and 119.44 μg / mg, respectively. The standard PB2 was subsequently used for cell experiments to study its hypoglycemic activity in HepG2-IR cells.
[0113] (2) HepG2 cell culture
[0114] 1) Cell culture medium replacement:
[0115] Complete cell culture medium is prepared by 45ml RPMI 1640 medium + 5mL fetal bovine serum FBS. Before use, place it in a water bath to preheat at 37℃. Take out the cell culture dish from the incubator and remove the old culture medium. Add 10mL of new culture medium and put it back in the incubator at 37℃ with 5% CO2.
[0116] 2) Cell passaging:
[0117] Preheat the culture medium, trypsin digestion solution, and PBS at 37℃, and subculture when the cells are 90% full. Aspirate the old culture medium and add PBS buffer to wash twice, 2mL each time. Aspirate the PBS, add 1mL of trypsin digestion solution, place in the incubator, and digest for 5 minutes. Take it out of the incubator and add 3mL of culture medium (serum contains trypsin inhibitors) to terminate the digestion. Puff 20 times to disperse the cells, collect the cells into a 15mL test tube, and centrifuge at 800rpm for 5 minutes. After centrifugation, remove the supernatant, add 2mL of culture medium again, and blow it into a cell suspension. Count the cells under a microscope according to the cell counting plate required for the experiment, then aspirate the appropriate number of cells and dilute them for inoculation.
[0118] 3) Cell cryopreservation:
[0119] The steps are basically the same as for passaging. After centrifugation, remove the supernatant, add 1-2 mL of freezing solution, and blow it into a cell suspension. Each freezing tube has 1 mL, and the number of frozen cells is >4 million.
[0120] (3) Cytotoxicity test
[0121] The principle of cytotoxicity is to detect the effect of the sample on cell activity based on the reducing ability of the cell. Take a 96-well plate, with about 5000-10000 cells per well and 100μL culture medium. After attachment, remove the culture medium, add LSE at a concentration of 0, 2.5, 5, 10, 20μg / mL and 0, 2.5, 5, 10, 20, 40μmol / mL PB2 to each well, and continue to culture in the incubator for 24h. After the culture is completed, remove the culture medium, add PBS to wash once, and then prepare the reaction solution with RPMI 1640 culture medium and CCK-8 solution at a ratio of 9:1, add 100μL to each well, and continue to incubate in a 37℃ incubator for 2h. Measure the absorbance at 450nm with an enzyme reader.
[0122] (4) Establishment of insulin resistance model
[0123] GlcN was used to construct an insulin resistance model. In a 96-well plate, about 2×104 cells were added to each well, and the fixed concentration was 18mM. The effects of different induction times of GlcN (0, 6, 12, 18, 24h) on insulin resistance in HepG2 cells were determined. According to the optimal time, the effects of different GlcN concentrations (0, 6, 12, 18mM) on insulin resistance were explored. The index of insulin resistance was determined by the change in glucose concentration in the supernatant of the cells in the culture medium. The glucose concentration in the supernatant was determined using a glucose oxidase kit.
[0124] To exclude the effect of GlcN on cytotoxicity, cytotoxicity was tested at concentrations of 0, 6, 12, 18, and 24 mM. Fig.11 It can be seen that GlcN has a certain cytotoxicity and reduces cell activity in a dose-dependent manner. When the concentration is 24mM, the cell activity is reduced to 68% relative to the blank group, which has a greater impact, while 18mM is 82%. A series of insulin resistance inducer GlcN (0, 6, 12, 18, 24mM) with a concentration gradient was added to the culture medium to induce an insulin resistance model of hepatocytes, and the cell absorption effect of glucose was used as a measurement indicator. Fig.12 It can be seen that the glucose absorption of cells in the blank group was 5.1mmol / L. After adding 6mM GlcN, the glucose absorption decreased to 3.7mmol / L. When the GlcN concentration was 18mM and 24mM, the glucose was only consumed by 3.0mmol / L and 2.6mol / L, both of which were significantly different from the blank group, indicating that insulin resistance had occurred. Therefore, after comprehensive consideration, 18mM was finally selected as the final induction concentration.
[0125] 18mmol / L GlcN was added to the cells to determine the effect of different culture times on the glucose consumption of the cells. Fig.13As shown in the figure, when no inducer is added, HepG2 cells consume 3.9mmol / L of glucose, and as the GlcN induction time increases, the consumption gradually decreases. When the GlcN induction time increases to 18h, the glucose consumption is 2.0mmol / L, which is significantly different from the blank group (P<0.05). The induction time of 18h was selected for the subsequent model construction. Therefore, the conditional concentration of GlcN inducing HepG2 cells to produce insulin resistance is determined to be 18mM, and the induction time is 18h, which can be used as a cell model for subsequent testing of hypoglycemic effects.
[0126] LSE and PB2 were selected for further testing. Fig.15 In the experiment, when the concentration of PB2 was 20μmol / L, the relative activity of cells was 89%, and at 40μmol / L, the cell activity dropped to 78%. When LSE was 5μg / mL, the cell activity was 87%, and at 10μg / mL, it was 81%. According to the cytotoxicity of PB2 and LSE, the concentration of LSE in the culture medium for subsequent treatment of cells was 2.5μg / mL for L-LSE group and 5μg / mL for H-LSE group, and the concentration of PB2 treatment was 10μmol / L for L-PB2 group and 20μmol / L for H-PB2 group. Fig.16 As shown in the results, the glucose uptake and consumption of glucose in the glucose-induced model was 1.8mmol / L, which was significantly different from the glucose consumption of 4.0mmol / L in the blank control group (P<0.05). Low-dose PB2 and LSE can promote the absorption of glucose by HepG2 cells, while high-dose PB2 basically restores the glucose consumption of HepG2 cells to 3.9mmol / L, which is significantly different from the model group (P<0.05). Both metformin and high-dose LSE promote the absorption of glucose by HepG2 cells in an insulin-resistant state, and there are significant differences (P<0.05). The results of the liquid chromatography analysis of LSE components and glucose consumption test showed that PB2 may be the main active ingredient in LSE, which can promote the absorption of glucose by HepG2-IR. The next step will be to analyze the mechanism of action of PB2 by protein immunoblotting.
[0127] (5) Western blot
[0128] The cells were used to establish an insulin resistance model according to the optimal conditions in (4). The cells were plated in 6-well plates with approximately 500,000 cells per well. After the cells adhered to the wall the next day, a culture medium containing 18 mM GlcN and 2% FBS was added and induced for 18 h. Different doses of PB2 (0, 10, 20 μmol / mL) were then added to treat the cells for 24 h, while phosphorylated proteins were only treated for 1 h. The proteins were then collected for western blot analysis.
[0129] In the results of protein immunoblotting, it was found that compared with the model group, the phosphorylation levels of IRS-1 in the metformin and PB2 groups were upregulated, 1.25 and 1.27, respectively, indicating that the insulin signaling pathway was reactivated ( Fig.17 In B). Fig.17 In (C), the phosphorylation expression of AKT, a downstream protein of IRS1, was significantly reduced in the model group to 0.28, while the high-dose and low-dose PB2 groups increased the phosphorylation expression of AKT to 0.63 and 1.65, respectively, with extremely significant differences (P<0.01).
[0130] Fig.17 Middle (D) indicates the expression of proteins related to the control of glycogen production. When hepatocytes absorb glucose to synthesize glycogen under the action of insulin, the phosphorylation expression of GSK-3β will increase. The relative levels of p-GSK-3β / GSK-3β ratios in the high- and low-dose groups of metformin and PB2 were 1.96, 2.32, and 2.25, respectively. This indicates that PB2 treatment upregulated GSK-3β phosphorylation and promoted glycogen synthesis.
[0131] Fig.17 (EF) in the figure indicates the expression of two proteins related to gluconeogenesis. When hepatocytes produce gluconeogenesis, the expression of two enzymes regulating this effect, PEPCK and G6pase, will increase. Fig.17 As shown in (E), compared with the blank control group, the relative protein expressions of the GlcN-induced model group were 1.09 and 1.38, respectively, while metformin and PB2 could reduce the expression of PEPCK and G6pase, among which high-dose PB2 had significant differences (P<0.05), with the relative expression level of PEPCK reduced to 0.86 and the relative expression level of G6pase reduced to 0.79.
[0132] Fig.17 The middle (G) indicates the expression of proteins related to controlling glucose transport into cells. As shown in the figure, the relative expression of GLUT2 in the model group was low, only 0.45. However, PB2 can upregulate the expression of GULT2 protein, and the protein expression in the high-dose PB2 group was 0.80, which was significantly different from the model group (P<0.05).
[0133] (6) Data processing and statistical analysis
[0134] ImageJ was used to analyze the gray value of protein bands, SPSS26 software was used for one-way ANOVA, Duncan method was used for pairwise comparison, P<0.05 was considered statistically significant, and Prism 8.0 was used to draw statistical graphs. All experiments were repeated three times in parallel, and the data were expressed as mean ± standard deviation.
[0135] This specific embodiment is merely an explanation of the present invention and is not a limitation of the present invention. After reading this specification, those skilled in the art may make non-creative modifications to the present embodiment as needed. However, as long as they are within the scope of the claims of the present invention, they are protected by the patent law.
Claims
1. A method for preparing a lotus seed pod extract, characterized in that: Take lotus pods, wash them, dry them in a drying oven at 55℃ for 8h, and grind them into powder using a pulverizer. Put the powder through a 100-mesh sieve into a frosted wide-mouth bottle, seal it, and place it in a refrigerator at 4℃ for later use. Take 1g lotus pod powder, add 60% ethanol solution in a solid-liquid ratio of 1:12, shake well, extract statically for 2.5h, the extraction temperature is 40℃, centrifuge at 10000r·min, 4℃ for 10min, take out the supernatant, and obtain lotus pod extract proanthocyanidins.
2. The use of the lotus seed pod extract according to claim 1, characterized in that: PB2, a main component of the lotus pod extract, reduces blood sugar in db / db mice and improves insulin resistance by restoring the liver insulin signaling pathway.
3. The use of the lotus seed pod extract according to claim 2, characterized in that: The lotus pod extract can be used to inhibit the activities of alpha-glucosidase and alpha-amylase.
4. The use of the lotus seed pod extract according to claim 2, characterized in that: A high dose of the lotus seed pod extract can increase the HDL content in blood lipids and significantly reduce the LDL content.
5. The use of the lotus seed pod extract according to claim 2, characterized in that: The lotus pod extract can reduce liver lipid accumulation, liver damage and oxidative stress in db / db mice, reduce the expression levels of ALT and AST, increase the expression levels of liver SOD, CAT and GSH, and reduce the level of MDA.
6. The use of the lotus seed pod extract according to claim 2, characterized in that: PB2, a main component in the lotus pod extract, can be used to promote HepG2 liver cells to consume glucose.
7. The use of the lotus seed pod extract according to claim 6, characterized in that: The lotus pod extract improves insulin resistance, upregulates IRS-1 and AKT phosphorylation, restores insulin signaling pathway conduction, and then activates downstream signaling pathways, increases GLUT2 expression and promotes glucose uptake; induces GSK-3β phosphorylation to promote glycogen synthesis; and downregulates PEPCK and G6pase to reduce glucose production.
8. Use of the lotus seed pod extract according to claim 2 in the preparation of hypoglycemic drugs, health products and hypoglycemic foods.
Citation Information
Patent Citations
Method of applying procyanidins from lotus seed pots to prevent brain oxidative stress injury caused by extremely low-frequency electromagnetic fields (ELF-EMF)
CN103156839A
Method for extracting procyanidine from receptaculum nelumbinis
CN103304532A
Binder, electronode, secondary battery, capacitor and manufacturing method for binder
KR1020240077862A
